A Potent SARS-CoV-2 Neutralizing Single-domain Antibody (SdAb) Shows Therapeutic Efficacy in the Syrian Golden Hamster Model of COVID-19
By
Creative Biolabs
0 Followers
Follow
Event Details
A Potent SARS-CoV-2 Neutralizing Single-domain Antibody (SdAb) Shows Therapeutic Efficacy in the Syrian Golden Hamster Model of COVID-19
Creative Biolabs has invited Dr. James Naismith to walk us through the development of his novel SARS-CoV-2 neutralizing sdAbs and how his team has found a candidate demonstrating promising therapeutic efficacy in a hamster model of COVID-19.
The following key points will be discussed in this webinar:
SdAbs which bind to SARS-CoV-2 have been identified from both naive library and llama challenge.
SdAbs target two broad epitopes, highlighting the role of E484 in first-generation agents.
It is possible to make two formulations that showed potency in a hamster therapeutic model.
The following key points will be discussed in this webinar:
SdAbs which bind to SARS-CoV-2 have been identified from both naive library and llama challenge.
SdAbs target two broad epitopes, highlighting the role of E484 in first-generation agents.
It is possible to make two formulations that showed potency in a hamster therapeutic model.
Entry Fees
Free Registration
Event Frequency
One Time
Event Timings
(GMT-7:00) Pacific Time (US and Canada)
11:00 AM - 12:00 PM (Oct 25) (General)
Organizer
Creative Biolabs
0 Followers
Follow
As one of the well-recognized service providers, Creative Biolabs always sticks to the Customer-first Principle and goal-oriented philosophy to serve our clients all over the world. Our well-trained full-time scientists can work closely with our r...
Comments on A Potent SARS-CoV-2 Neutralizing Single-domain Antibody (SdAb) Shows Therapeutic Efficacy in the Syrian Golden Hamster Model of COVID-19
You must Login to write a comment.
Peoples Interested in Visit
0 Peoples Interested to Visit
Event Location
Official Link :